As such, our findings that Vipr2ΔILC3 mice under an HFD maintain higher levels of IL-22 production by ILC3 in comparison to WT littermate control mice and concurrently have reduced liver steatosis suggest immune-metabolic interactions are an important therapeutic avenue worth further investigating in MASLD. Here, IL22 is linked to metabolic dysfunction-associated steatotic liver disease.